相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
Miwako Narita et al.
International Journal of Medical Sciences (2012)
Oncosuppressive Functions of Autophagy
Eugenia Morselli et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer
Norio Nonomura et al.
BJU INTERNATIONAL (2011)
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
Y. Wang et al.
BRITISH JOURNAL OF CANCER (2011)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson et al.
CANCER CELL (2011)
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells
Timothy J. Haggerty et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
Sylvain Ladoire et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Sophie Viaud et al.
CANCER RESEARCH (2011)
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Giovanna Schiavoni et al.
CANCER RESEARCH (2011)
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Stephen R. Mattarollo et al.
CANCER RESEARCH (2011)
mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
Qun Jiang et al.
CANCER RESEARCH (2011)
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice
Bethany L. Mundy-Bosse et al.
CANCER RESEARCH (2011)
Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy
Niels Halama et al.
CANCER RESEARCH (2011)
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Yoshihiro Komohara et al.
CANCER SCIENCE (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia
Simone Boehrer et al.
CELL CYCLE (2011)
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
Jon Amund Kyte et al.
CLINICAL CANCER RESEARCH (2011)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Brian P. Pollack et al.
CLINICAL CANCER RESEARCH (2011)
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Jan Pander et al.
CLINICAL CANCER RESEARCH (2011)
CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Christine Zoglmeier et al.
CLINICAL CANCER RESEARCH (2011)
Cimetidine: An anticancer drug?
Martina Kubecova et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
Magdalena Winiarska et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice
Manuela Gonzalez-Aparicio et al.
GUT (2011)
Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma
Peter Kamper et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma
Giuseppe Sconocchia et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
Ingrid M. E. Desar et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells
Lorna Rettig et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Bystander effect of vinorelbine alters antitumor immune response
Audrey Thomas-Schoemann et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival
Kelly G. Paulson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High Levels of Antibodies Against Merkel Cell Polyomavirus Identify a Subset of Patients With Merkel Cell Carcinoma With Better Clinical Outcome
Antoine Touze et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multifactorial Approach to Predicting Resistance to Anthracyclines
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Alexander Pedroza-Gonzalez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
Lucia De Monte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy
Yuting Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells
Jose Medina-Echeverz et al.
JOURNAL OF IMMUNOLOGY (2011)
Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Greta Garrido et al.
JOURNAL OF IMMUNOLOGY (2011)
DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity
Jennifer L. Guerriero et al.
JOURNAL OF IMMUNOLOGY (2011)
Circulating Antibodies to Carcinoembryonic Antigen Related to Improved Recurrence-free Survival of Patients with Colorectal Carcinoma
X-J Wu et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions
Alessandra Nardin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire et al.
JOURNAL OF PATHOLOGY (2011)
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye et al.
NATURE MEDICINE (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Cancer immunotherapy - revisited
W. Joost Lesterhuis et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Mitotic catastrophe: a mechanism for avoiding genomic instability
Ilio Vitale et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma
Bi Cheng Zhang et al.
MEDICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
Imatinib Treatment Induces CD5+B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia
Silvia Catellani et al.
PLOS ONE (2011)
Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates
John T. Norton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4
Y. Zhu et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway
Qiong Luo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2011)
Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
Kamel Ait-Tahar et al.
BLOOD (2010)
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
Raphael Marechal et al.
BMC CANCER (2010)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
W. J. Lesterhuis et al.
BRITISH JOURNAL OF CANCER (2010)
CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Kavya Rakhra et al.
CANCER CELL (2010)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L. Gulley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients
Florian Cabillic et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma
Martin Poelcher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients
Belinda Palermo et al.
CANCER RESEARCH (2010)
Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death
Roberta Zappasodi et al.
CANCER RESEARCH (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Decoding Cell Death Signals in Inflammation and Immunity
Laurence Zitvogel et al.
CELL (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
VEGF Blockade Inhibits Lymphocyte Recruitment and Ameliorates Immune-Mediated Vascular Remodeling
Jiasheng Zhang et al.
CIRCULATION RESEARCH (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib
Ulrike Heider et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Cardiac side-effects of cancer chemotherapy
Jean-Jacques Monsuez et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer
Melissa A. Geller et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Higher intratumoral infiltrated Foxp3+Treg numbers and Foxp3+/CD8+ratio are associated with adverse prognosis in resectable gastric cancer
Zhengbin Shen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice
Jane E. Dalton et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome
Johan Staaf et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Spectral Clustering of Microarray Data Elucidates the Roles of Microenvironment Remodeling and Immune Responses in Survival of Head and Neck Squamous Cell Carcinoma
Johanna K. Thurlow et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IAP inhibitors enhance co-stimulation to promote tumor immunity
Michael Dougan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase
Andrea Schietinger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells
Daisuke Muraoka et al.
JOURNAL OF IMMUNOLOGY (2010)
Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy
Pierpaolo Correale et al.
JOURNAL OF IMMUNOTHERAPY (2010)
A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
Olivier Adotevi et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis
Faraaz B. Chekeni et al.
NATURE (2010)
Personalized medicine in oncology: the future is now
Richard L. Schilsky
NATURE REVIEWS DRUG DISCOVERY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
M. Manzoni et al.
ONCOLOGY (2010)
BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs
Emma M. Carrington et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Jacqueline D. Shields et al.
SCIENCE (2010)
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α
Matthew Kraman et al.
SCIENCE (2010)
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Mads Gyrd-Hansen et al.
NATURE REVIEWS CANCER (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial
N. Schoof et al.
ANNALS OF ONCOLOGY (2009)
Dasatinib inhibits the proliferation and function of CD4(+)CD25(+) regulatory T cells
Fei Fei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer
Angela DeMichele et al.
CANCER RESEARCH (2009)
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
Cedric Menard et al.
CANCER RESEARCH (2009)
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Hong Xin et al.
CANCER RESEARCH (2009)
Chemotherapy induces ATP release from tumor cells
Isabelle Martins et al.
CELL CYCLE (2009)
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
G. Kroemer et al.
CELL DEATH AND DIFFERENTIATION (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
The immunogenicity of tumor cell death
Oliver Kepp et al.
CURRENT OPINION IN ONCOLOGY (2009)
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis et al.
EMBO JOURNAL (2009)
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
Cara K. Fraser et al.
EXPERIMENTAL HEMATOLOGY (2009)
Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo
Cara K. Fraser et al.
EXPERIMENTAL HEMATOLOGY (2009)
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
Belen Blanco et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection
Tong Ding et al.
HUMAN PATHOLOGY (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients
Paola Nistico et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression
Hiroshi Fujimoto et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
Galina V. Shurin et al.
JOURNAL OF IMMUNOLOGY (2009)
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2009)
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
Ramon Kaneno et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: Prognostic impact may depend on type of treatment and stage of disease
Luitpold V. Distel et al.
ORAL ONCOLOGY (2009)
Immunogenic and tolerogenic cell death
Douglas R. Green et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Development and dynamics of robust T-cell responses to CML under imatinib treatment patients
Christiane I-U. Chen et al.
BLOOD (2008)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Tumor cell metabolism: Cancer's Achilles' heel
Guido Kroemer et al.
CANCER CELL (2008)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
Mareike Schmudde et al.
CANCER LETTERS (2008)
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells
Sylvain Ladoire et al.
CLINICAL CANCER RESEARCH (2008)
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing
Mala Chakraborty et al.
CLINICAL CANCER RESEARCH (2008)
Combination of docetaxel and recombinant vaccine enhances T-Cell responses and antitumor activity: Effects of docetaxel on immune enhancement
Charlie T. Garnett et al.
CLINICAL CANCER RESEARCH (2008)
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
Ralf Weichsel et al.
CLINICAL CANCER RESEARCH (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic significance of macrophage infiltration in leiomyosarcomas
Cheng-Han Lee et al.
CLINICAL CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Stephen Blake et al.
CLINICAL IMMUNOLOGY (2008)
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens
Fei Fei et al.
EXPERIMENTAL HEMATOLOGY (2008)
Factors regulating apoptosis and homeostasis of CD4+CD25highFOXP3+ regulatory T cells are new therapeutic targets
Xiao-Feng Yang
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells
Carsten Berges et al.
IMMUNOLOGY (2008)
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
J. Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer
Vincenzo Pitini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
Nicolas Larmonier et al.
JOURNAL OF IMMUNOLOGY (2008)
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
Sylvia Adams et al.
JOURNAL OF IMMUNOLOGY (2008)
Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcγRs on human dendritic cells
Devi Baneijee et al.
JOURNAL OF IMMUNOTHERAPY (2008)
AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma
Daniel L. Albertus et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Erlotinib exhibits antineoplastic off-target effects in AML and MDS:: a preclinical study
Simone Boehrer et al.
BLOOD (2008)
Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis
Gabrielle S. Sellick et al.
BLOOD (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Oncogenes and tumour suppressors take on centrosomes
Kenji Fukasawa
NATURE REVIEWS CANCER (2007)
Impact of interleukin-10 polymorphisms (-1082 and-3575) on the survival of patients with lymphoid neoplasms
Eva Domingo-Domenech et al.
HAEMATOLOGICA (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Modulation of T-effector function by imatinib at the level of cytokine secretion
Christoph Leder et al.
EXPERIMENTAL HEMATOLOGY (2007)
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non-small-cell lung cancer
Geoffrey Chan et al.
BLOOD (2007)
Prognostic significance of host immune gene polymorphisms, in follicular lymphoma survival
James R. Cerhan et al.
BLOOD (2007)
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
Junliang Fu et al.
GASTROENTEROLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Interleukin-4 promoter polymorphisms: A genetic prognostic factor for survival in metastatic renal cell carcinoma
Thomas Kleinrath et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo
Parisa Sinai et al.
JOURNAL OF IMMUNOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients
Rebecca P. Petersen et al.
CANCER (2006)
Stattic: A small-molecule inhibitor of STAT3 activation and dimerization
Jochen Schust et al.
CHEMISTRY & BIOLOGY (2006)
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
Ian D. Davis et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni et al.
BLOOD (2006)
Drug interactions in cancer therapy
Charity D. Scripture et al.
NATURE REVIEWS CANCER (2006)
Chemoimmunotherapy of tumors:: Cyclophosphamide synergizes with exosome based vaccines
Julien Taieb et al.
JOURNAL OF IMMUNOLOGY (2006)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
PM Arlen et al.
CLINICAL CANCER RESEARCH (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer
C Bourquin et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia
H Gao et al.
LEUKEMIA (2005)
Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma:: A quantitative tissue microarray study in a large retrospective cohort of 267 patients
T Alvaro-Naranjo et al.
LEUKEMIA & LYMPHOMA (2005)
Gefitinib induces myeloid differentiation of acute myeloid leukemia
K Stegmaier et al.
BLOOD (2005)
Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis
BN Cronstein
PHARMACOLOGICAL REVIEWS (2005)
The role of tumor stroma in the interaction between tumor and immune system
T Blankenstein
CURRENT OPINION IN IMMUNOLOGY (2005)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Timeline - Chemotherapy and the war on cancer
BA Chabner et al.
NATURE REVIEWS CANCER (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Friends or foes - Bipolar effects of the tumour stroma in cancer
MM Mueller et al.
NATURE REVIEWS CANCER (2004)
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
AK Nowak et al.
JOURNAL OF IMMUNOLOGY (2003)
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Y Hamanaka et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Induction of TNF-alpha, mu PA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells
M Niiya et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
HL Weiner et al.
MULTIPLE SCLEROSIS JOURNAL (2002)
分享论文
